conservatively with intravenous heparin, followed by subcutaneous heparin and clopidogrel. He responded well to medical therapy and remains under vascular follow up. Notably, the aneurysm was retrospectively noted on CT scan imaging, confirming that it predated corticosteroid treatment. Key learning points: Whilst aneurysm formation is a recognised complication of giant cell arteritis, they are typically aortic and involvement of lower limb arteries is rare There is no consensus opinion on optimal surveillance of extra-aortic aneurysmsin GCA; decisions should be made ona case by case basis Tocilizumab is an effective treatment for refractory GCA. The current NICE guideline onits usage is based onthe GiACTA studyfindings Conflicts of interest: The authors have declared no conflicts of interest.
GCA: DIAGNOSED WITH A HEAVY HEART
Samir Patel 1 , Israa Al-Shakarchi 1 , and Dobrina Hull 1 1 Rheumatology, Kingston Hospital, London, United Kingdom Introduction: Giant cell arteritis (GCA) represents a common cause of uncertainty for physicians. GCA can present as an indolent or aggressive process with a wide spectrum of symptoms and signs. The key to diagnosis is good clinical acumen and awareness of both common and rare associated conditions. Here we describe a rare and atypical presentation of a patient with GCA and chest pain. Case description: An 83-year old male was admitted to the medical take with 3 hours of crushing chest pain associated with diaphoresis and nausea. He had been started on 60mg prednisolone by his GP 3 days preceding this for suspected GCA (scalp tenderness, jaw claudication, polymyalgia). Past medical history included: hypertension, recent strokes (bilateral cerebellar infarcts 3 months prior), previous DVTs and COPD. Examination revealed no abnormalities. Admission ECGs showed sinus rhythm with fixed T-wave inversion in aVL and V3. Chest radiograph was normal. Bloods tests revealed mildly raised inflammatory markers (CRP, ESR 24) and a dynamic troponin (324 -1241 -1431 ng/L). He was diagnosed with a non-ST elevation myocardial infarction (NSTEMI) and was referred to Cardiology for an angiogram. He was started on dual antiplatelets and high dose atorvastatin. On review by Rheumatology, his recent history of bilateral posterior circulation strokes was investigated further. Multi-level bilateral vertebral artery stenosis was seen on CT angiogram at the regional hyper-acute stroke unit and diagnosed as atheromatous in origin due to: a negative right-sided temporal artery biopsy, no GCA symptoms and modest inflammatory markers (CRP inthe 30sand ESR in the 20s). Due to the onset of clear and acute GCA symptoms a left-sided temporal artery biopsy and PET scan was scheduled. Prednisolone was reduced to 40mg OD due to concern over its atherogenicity during a suspected NSTEMI. Coronary angiogram went on to show clear arteries and a subsequent cardiac MRI confirmed acute myocarditis. The left temporal artery biopsy revealed chronic inflammation with scatteredgiant cells. The patient was diagnosed with: GCA, extra-cranial vasculitis and myocarditis. He was treated with intravenous methylprednisolone, a weaning course of prednisolone and started onmethotrexate (15mg weekly). The patient's chest pain settled soon after admission and his troponin and inflammatory markers fellwith prednisolone. Discussion: GCA seldom presents with myocarditis and can lead to significant morbidity and mortality. This remains an important differential in a patient with clear GCA features and chest pain. This case report adds to the growing body of evidence that myocarditis is a recognised feature of GCA. A literature review revealed 8 articles and a total of 9 patients with GCA who presented with or developed myocarditis. The initial diagnosis of an NSTEMI was reasonable in this case and the most probable cause of the patient's symptoms, signs and blood results at the time. To this end, starting dual anti-platelets was justified. His prednisolone was reduced to 40mg due to concerns over accelerated atherosclerosis with high dose glucocorticoids in an already high-risk male with smoking history, hypertension and a stroke history. In retrospect, this was an unnecessary step, but arguably reasonable when weighing the risks and benefits of one treatment against a simultaneous acute illness (NSTEMI). Each subsequent investigation helped to diagnose and exclude certain conditions: the angiogram was necessary to exclude an acute coronary syndrome; cardiac MRI then went on to provide evidence of myocarditis; temporal artery biopsy confirmed GCA and a PET scan excluded any significant large vessel involvement. Interestingly, the first right-sided temporal artery biopsy 3 months prior was negative but the second left-sided biopsy was diagnostic. The BSR states that "contralateral biopsy is usually unnecessary"; however, a few studies have found discordant results when carrying out simultaneous bilateral biopsies with an increased diagnostic yield (Boyev et al., 1999; Breuer et al., 2009 and Durling et al., 2014) , suggesting bilateral temporal artery biopsies could lead to less treatment delaysand more accurate diagnoses. Key learning points: Myocarditis is a recognised complication of giant cell arteritis. The key to diagnosis here was a thorough history and an open mind with regards to his background, particularly the bilateral strokes. Investigations initially did not support GCA-associated myocarditis. But the preceding typical GCA symptoms and recent strokes raised the suspicion of a more systemic vasculitis. Working off others' diagnosis can be misleading. The very recent bilateral posterior circulation strokes and vertebral artery abnormalities were overlooked on admission due to being thoroughly worked up and disregardedas vasculitic bya tertiary stroke centre. Conflicts of interest: The authors have declared no conflicts of interest.
CLAUDICATION, CEREBRAL INFARCT AND CYCLOPHOSPHAMIDE
Jeeu Teck Sze 1 1 Rheumatology, Countess of Chester Hospital, Chester, United Kingdom Introduction: We present a severe and rare case of GCA involving the right middlecerebral artery (MCA) resulting in an ischaemic stroke. Our patient presented in 2017, before tocilizumab was approved as a treatment option in refractory GCA. Intravenous cyclophosphamide was used as a glucocorticoid-sparing agent in this patient with good response. This case contributes to our current limited evidence base in the treatment and prognosis of intracranial GCA. Case description: The patient was 75 years old when referred by his GP with a four-month history of left temporal headache, jaw claudication and weight loss in August 2017. He had type 2 diabetes and hypertension. He alsohadastroke in2015 andwassubsequentlyfoundtohaveparoxysmal atrial fibrillation so was commenced onrivaroxaban. His bloods showed ESR of 66 and CRP 18. ESR had been persistently raised for two months. Ophthalmology assessment revealed bilateral cataracts only. A clinical diagnosis of GCA was made and he was commenced onprednisolone 60mg daily. A biopsy of his left temporal artery was performed six days later and the histology showed transmural inflammation with multinucleated giant cells. His headache and jaw claudication improved with prednisolone but he was still experiencing localised temporal artery tenderness. In the last week of September 2017, he presented to the Emergency Department with a two-day history of incoordination and left arm weakness. MRI of his head showed small foci of infarcts in the right MCA territory. He had suffered an ischaemic stroke likely secondary to GCA despite being treated with high dose oral glucocorticoid. He was given three pulses of intravenous methylprednisolone followed by intravenous cyclophosphamide. Subsequent CT angiogram (CTA) confirmed the involvement of intracranial arteries -circumferential thickening of the right internal carotid artery with near complete occlusion of right cavernous and intracranial segments. There was also mural thickening involving the left vertebralartery. Hewentontohave fivemorecyclesofcyclophosphamideandresponded well to treatment. Oral methotrexate 15mg weekly was added in two weeks after the last course of cyclophosphamide. During his last clinic visit, he was taking prednisolone 2mg daily and the plan was to taper the dose downto zero over eight weeks. Discussion: Though uncommon, GCA can affect vertebrobasilar arteries causing strokes. The involvement of intracranial arteries, on the other hand, is thought to be extremely uncommon in GCA due to their increased wall thickness. There is only a limited number of intracranial GCA cases reported in the medical literature. A review of nearly 500 patients with a diagnosis of central nervous system vasculitis at the Mayo Clinic identified only two patients with convincing evidence of intracranial GCA. Our patient's MRI and CTA were reviewed in the neuroradiology multidisciplinary meeting and the consensus was that there was a near complete occlusion of the right MCA due to avasculiticprocess. Importantly, his GCA went into remission and he has not had any relapses thus far (21 months since his initial presentation). He has also improved from the stroke point of view. We have been able to reduce his prednisolone dose to aminimallevel. The use of oral or intravenous cyclophosphamide in the treatment of refractory GCA have been reported. It was found to be effective in inducing a sustained remission in a majority of patients in a series of 35 patients POSTER PRESENTATIONS 27 September 2019 i41
